全国服务咨询热线:

13761418683

Products产品中心
首页 > 产品中心 > 生化试剂 > 小分子化合物 > abs47027912Dorzolamide hydrochloride 130693-82-2

Dorzolamide hydrochloride 130693-82-2

简要描述:Dorzolamide hydrochloride 130693-82-2
Dorzolamide Hydrochloride is the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase

  • 产品型号:abs47027912
  • 厂商性质:生产厂家
  • 更新时间:2026-01-07
  • 访  问  量:578

详细介绍

品牌absinCAS130693-82-2
分子式C10H17ClN2O4S3纯度99%
分子量360.9货号abs47027912
规格5mg供货周期现货
主要用途is the hydrochloride salt form of dorzol应用领域化工,生物产业,农林牧渔,制药/生物制药,综合

Dorzolamide hydrochloride  130693-82-2

产品描述
描述

Dorzolamide Hydrochloride is the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions. Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis.

纯度
99%
储存/保存方法
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
基本信息
别名
盐酸多佐胺;L671152 hydrochloride;MK507 hydrochloride
外观
白色粉末
可溶性/溶解性
Water : 12 mg/mL (33.3 mM)
生物活性
靶点
Carbonic anhydrase II,Carbonic anhydrase IV,Carbonic anhydrase I
In vitro(体外研究)
Dorzolamide is a powerful inhibitor of carbonic anhydrase (CA) II that penetrates the sclera and cornea to reach the ciliary process and lowers formation of HCO3 and aqueous humor. Dorzolamide causes a vasodilatation of retinal arteries, pre-contracted by three different mechanisms by direct action and presumably independent of changes in extracellular pH.
In vivo(体内研究)
Dorzolamide, administered twice and three times daily, significantly decreases intraocular pressure (IOP) in glaucomatous dogs on the first day (twice daily 7.6 mmHg, and three times daily 16.4 mmHg) that is even greater by day 5 (twice daily 10.4 mmHg, and three times daily 13.9 mmHg). Dorzolamide (instilled in the drug eye for day 1 through to day 5) combined with oral methazolamide (administered from day 3 through to day 5) significantly lowers IOP in the eye on day 1, for day 3 and for all of day 5 for both eyes. Dorzolamide (2%) instilled three times daily produces similar IOP declines compared to the combination of oral methazolamide and 2% dorzolamide administered twice daily. Dorzolamide hydrochloride induces a very large IOP reduction and is found to be also well effective at night in rabbit. Dorzolamide maximally lowers the intraocular pressure (IOP) of glaucomatous monkeys by 22%, 30% and 37%, respectively.
参考文献
参考文献
  • 1. Maren TH, et al. J Ocul Pharmacol Ther, 1997, 13(1), 23-30.

  • 2. Percicot CL, et al. J Pharmacol Toxicol Methods, 1996, 36(4), 223-228.

  • 3. Josefsson A1, et al. Exp Eye Res, 2004, 78(2), 215-221.

研究领域
研究领域
Drug DiscoverySmall Molecule DrugLead Compound Discovery
Dorzolamide hydrochloride  130693-82-2温馨提示:本产品仅作科研实验使用,不支持临床等研究

产品咨询

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
爱必信(上海)生物科技有限公司
地址:上海市浦东新区新浩路58号申江科创园18栋
邮箱:zhouzz@univ-bio.com
传真:
关注我们
欢迎您关注我们的微信公众号了解更多信息:
欢迎您关注我们的微信公众号
了解更多信息